We are dedicated to innovation, quality and safety
We aim to deliver safe & effective therapies to quickly & painlessly help restore visual acuity and quality of life for late stage low vision patients
Welcome to
Compass Health AI
Empowering lives affected by Late Stage Macular Disease and Low Central Vision
Raymond Stein, MD, FRCSC
“The treatment is easy for patients to undergo and the safety profile is superior to any other surgical treatment in ophthalmology.” “There is no downside to this superficial corneal treatment.” “such a benign treatment”.
Medical Director, Bochner Eye Institute; Associate Professor of Ophthalmology, University of Toronto; internationally recognized expert on corneal, refractive and cataract surgery with over 30 years of experience in performing over 100,000 successful eye surgeries; former President, Canadian Society of Cataract and Refractive Surgery.
Emrullah Tasindi, MD
“The Clear-K® procedure is much safer than any other corneal procedure such as corneal incision for cataract surgery and corneal flap generation for LASIK that is routinely performed by corneal, refractive and cataract surgeons”. “The device is not potentially hazardous.”
Chairman and Professor of Ophthalmology, Okan University; internationally recognized expert on corneal, refractive and cataract surgery; former Director, European Society of Cataract and Refractive Surgery; Principal Investigator – Clear-K® Clinical Study for Vision Improvement for Patients with AMD
W. Bruce Jackson, MD, FRCSC
“You have a safe treatment – much safer than (anti-VEGF intravitreal) injections – that can change the lives of many of these (AMD) patients.”
Former Chairman and Professor of Ophthalmology, Ottawa Eye Institute, University of Ottawa; Former President, Association of Canadian University Professors of Ophthalmology; internationally recognized expert on corneal, refractive and cataract surgery; Recipient, Lifetime Achievement Award, Canadian Ophthalmological Society; Recipient, Castroviejo Medal, Cornea Society; Recipient, American Academy of Ophthalmology Senior Achievement Award
David Sliney, PhD
“it seems clear that the procedure is NSR(Non-Significant Risk) for AMD patients (with vision loss)”
Internationally recognized expert on laser/ocular safety, consultant to FDA and regulatory organizations, co-author (with Myron Wolbarsht, MD, a clinical ophthalmologist)
Individual results may vary
Macular disease reduces visual acuity significantly
Compass’ laser treatment makes a small adjustment to the cornea
Light is redirected to the part of your retina that is still working
Vast majority of patients experience an immediate increase in visual acuity
Visual acuity continues to increase for vast majority of patients as brain adjusts
These images are approximations and not exact representations of vision for people with AMD
